Compare Marvell Technology Inc (MRVL) vs Sana Biotechnology Inc (SANA) Price & Performance

Marvell Technology IncTrade

Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Marvell Technology Inc vs Sana Biotechnology Inc — how do they compare? Marvell Technology Inc trades at $212.55 (market cap $171.11B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Marvell Technology Inc is far larger — about 195.8× Sana Biotechnology Inc's market cap, and Marvell Technology Inc pays a 0.12% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

	MRVL	SANA
Market Cap	$171.11B	$873.84M
Sector	Technology	Health
52-Week High	$316.43	$5.92
52-Week Low	$62.31	$2.68
Enterprise Value	$172.55B	$848.03M
Dividend Yield	0.12%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRVL

Chip stocks and strong earnings lift U.S. futures amid ceasefire hopes easing oil prices.FXEmpire · 12 hours agoBullish Global Ethernet Controller Market to reach $25.44B by 2035 driven by AI, cloud, and 5G growthSns Insider · 14 hours agoBullish View details →

SANA

View details →

About Marvell Technology Inc

Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.